Hydrogen Therapy: What the Term Really Means and Why TANVEA Uses Hydrogen Systems™

In summary: a scientific term is not automatically a therapeutic promise

The term hydrogen therapy is appearing with increasing frequency. It can be found in scientific reviews, clinical studies, medical-gas research and materials science developing new systems for targeted delivery of molecular hydrogen. At the same time, the same expression is used commercially to describe hydrogen water, inhalation devices, baths, capsules, generators and almost any product associated with H₂. This is where the problem begins: the same term can carry very different weight in science and in marketing.

In scientific literature, molecular hydrogen therapy is a legitimate research term. A review published in Molecules in 2023 assessed 81 identified clinical trials and 64 scientific publications containing human data. The authors examined not only the reported outcomes, but also whether H₂ could eventually have a role as a therapeutic substance, how it might be administered and in which indications it might be relevant. That is a serious scientific question. It is not the same thing as claiming that a consumer H₂ product available today is an established treatment.

TANVEA therefore does not reject the term hydrogen therapy. On the contrary, we want to explain it more accurately than the market usually does. In our language, it may be the question that first brings someone to molecular hydrogen, but the final framework remains TANVEA Hydrogen Systems™. The word Systems deliberately avoids implying that a product treats disease. It reflects the fact that molecular hydrogen needs to be understood as a system involving the H₂ source, route of exposure, concentration or inspired fraction, time, distribution, biological response and quality of evidence.

What science actually means by “hydrogen therapy”

Hydrogen therapy is not currently one procedure with one dose and one standardised protocol. The scientific H₂ field includes molecular hydrogen inhalation, consumption of hydrogen-rich water, experimental administration of H₂-rich saline and increasingly sophisticated local or targeted delivery systems. This is precisely why a 2026 review in Advanced Drug Delivery Reviews devotes considerable attention to delivery itself: low solubility, high diffusivity, rapid elimination and the difficulty of maintaining stable and targeted exposure remain major challenges in translating H₂ from experimental research into clinical practice.

This is fundamentally different from the marketing shortcut. If two devices “use hydrogen”, that does not mean they create the same exposure. If a study uses inhaled H₂ under a precisely defined protocol, its result does not automatically apply to a hydrogen water bottle. If researchers generate H₂ locally within tissue, that result cannot simply be attributed to hydrogen bathing. And if an interesting result appears in a specific clinical population, it does not mean the same outcome will occur in a healthy person using a consumer technology.

This is why the TANVEA framework SOURCE → EXPOSURE → DISTRIBUTION → RESPONSE matters. A biological response does not begin with the word hydrogen. It begins with what H₂ source is being used, what exposure is actually created, where and how the molecule reaches the body, and what follows in that particular biological context.

From “selective antioxidant” to a much more complex picture of H₂

Modern molecular-hydrogen research was strongly influenced by the work of Ohsawa and colleagues published in Nature Medicine in 2007. Their study demonstrated biologically interesting selective effects of H₂ against highly reactive oxidative species and became one of the major catalysts for subsequent research. This historical framework was extremely important, but today’s state of knowledge can no longer be summarised by the sentence “hydrogen is an antioxidant”.

Contemporary redox biology does not regard every reactive oxygen species as an enemy. ROS have physiological roles in signaling, adaptation and immune responses. It is also increasingly clear that the broad and sometimes relatively persistent biological responses described after H₂ exposure are difficult to explain solely through the direct scavenging of one class of radicals. Reviews published in 2026 therefore organise the H₂ field around broader themes including redox homeostasis, mitochondrial quality control, mitophagy, metabolic adaptation and regulatory pathways. At the same time, the upstream initiating mechanism and its dependence on biological context remain unresolved.

This shift is particularly important for TANVEA. We do not want to promote molecular hydrogen as “the strongest antioxidant”, because such language conceals rather than explains biological complexity. It is more accurate to discuss redox modulation, the mitochondrial environment and regulatory responses, while clearly separating mechanistic plausibility from clinically demonstrated outcomes.

RISP, Complex III and UPRmt: evidence that H₂ is not biologically inert

An important mechanistic development came from work by Negishi and colleagues published in Redox Biology in late 2025. In cellular and mouse models, the researchers described a response involving the Rieske iron-sulfur protein RISP in mitochondrial Complex III, LONP1-dependent degradation of RISP and activation of the mitochondrial unfolded protein response, UPRmt. Under experimental conditions, H₂ transiently affected Complex III activity, and the authors identified RISP as a primary target of H₂. Their findings directly challenged the older idea of H₂ as a biologically inert molecule acting only through selective radical scavenging.

Science, however, did not stop with one new explanation. Early in 2026, Ostojic argued in Redox Biology that RISP may indeed be an important mediator, but that calling it the single primary molecular entry point for H₂ may be premature. Other mitochondrial Fe-S proteins and redox-sensitive structures may also form part of the wider mechanism. This is exactly how science should develop: a new result expands the model without automatically becoming a new dogma.

For TANVEA, this leads to an important linguistic refinement. Molecular hydrogen is not a performance stimulant. That does not mean it is biologically passive. If H₂ can induce regulatory and adaptive mitochondrial responses in experimental models, the simple statement “hydrogen is not a stimulus” is no longer scientifically precise enough.

Fe-porphyrins and hematin: another mechanistic line, not a new reason for exaggerated claims

At the end of August 2026, another important review appeared in the Journal of Cardiology. Its authors develop a mechanism involving oxidised Fe-porphyrins and hematin, proposing hematin as a redox biosensor and catalytic intermediary that may help explain the biological effects of H₂ at the atomic and chemical level. The authors themselves describe this as a potential paradigm shift in hydrogen medicine.

TANVEA will not turn even this highly interesting work into the statement “we now know exactly how hydrogen works”. RISP/Complex III and oxidised Fe-porphyrins represent two important mechanistic lines, while broader research into mitochondrial quality control and metabolic regulation suggests an even more complex network. The scientifically responsible conclusion today is not that the H₂ mechanism has been solved. It is that the traditional model of a simple selective antioxidant is probably insufficient and a substantially more complex understanding of H₂ biology is emerging.

That is stronger than marketing, because it gives a brand the authority to communicate not only what science has discovered, but also what remains unknown.

“Therapy” in science and “therapy” in marketing are not the same thing

The word therapy is legitimate in scientific literature. It is used in the 2023 review of clinical studies, the 2026 review of delivery systems discusses therapeutic applications, and the recent Journal of Cardiology review uses the term hydrogen medicine. It would therefore be incorrect to say that hydrogen therapy itself is pseudoscientific. It is not. The term has a legitimate place in biomedical research.

The problem begins in the next step: when a scientific term is transferred to a specific consumer product and all the important intermediate steps disappear. A mechanistic study in cells or mice is not evidence of a clinical effect in humans. A small human study in one population is not proof of a universal benefit. A result achieved through one route of exposure is not automatically the result of another route. And the fact that molecular hydrogen is being investigated as a potential therapeutic agent does not prove the therapeutic effect of a particular bottle, inhaler or bath generator.

For TANVEA, this is one of the most important boundaries in the entire category. We can communicate scientific research on H₂. Therapeutic claims must remain limited to what the specific evidence actually demonstrates.

Mechanism, human signal and clinical evidence are not the same level of knowledge

The molecular-hydrogen field is producing an increasing amount of interesting data, but not all evidence carries the same weight. A mechanistic experiment may show that a biological process is possible. An animal model may demonstrate that the process can occur in a whole organism under defined conditions. A small human study may provide an early signal. More robust conclusions require reproducible, well-controlled human data in relevant populations.

A useful current example is a randomised controlled crossover study published in September 2026. Thirteen male university athletes consumed hydrogen-rich water before a repeated sprint protocol, and the investigators reported differences in several performance, HRV and lactate-related parameters. It is an interesting human finding and shows that H₂ research continues to generate new questions. But it involved only 13 young men and one highly specific acute protocol. It would therefore be scientifically inappropriate to turn this signal into the statement that “hydrogen therapy improves sports performance”.

This kind of distinction is not excessive caution. It is the foundation of trust. TANVEA does not want to use scientific terminology as decoration for marketing. We want to show how strong a particular piece of evidence is and how large a conclusion it genuinely allows us to draw.

Molecular hydrogen is not a performance stimulant — but this statement needs to be understood correctly

The original article used the formulation that hydrogen “is not a stimulus”. It was a response to a culture of aggressive biohacking in which every product is presented as another boost, another source of energy or another route to higher performance. In that context, the idea remains valid: molecular hydrogen is not caffeine, it is not metabolic fuel, and TANVEA does not position it as a technology whose value lies in an immediate sensation of activation.

New mechanistic research, however, suggests that H₂ can function biologically as an input capable of modifying regulatory processes. It is therefore no longer sufficient to say “hydrogen is not a stimulus” without clarification. The more precise statement is that H₂ is not another performance stimulant, but a biologically active molecule whose role is being investigated in redox, mitochondrial and regulatory signaling.

This refinement does not change the philosophy of Hydrogen Systems™. It makes it more precise. TANVEA no longer describes hydrogen merely as a passive “protective layer”. We describe it as a protective and regulatory layer, while a separate SYSTEMS article explains in detail how this principle fits into the wider architecture of TANVEA Biological Systems™.

Hydrogen therapy is not one dose: the route of exposure fundamentally changes the biological context

One of the greatest mistakes in H₂ marketing is to talk about “hydrogen” without specifying the route of exposure. Hydrogen water, inhalation and bathing all use the same H₂ molecule, but from a biophysical and pharmacokinetic perspective they are not the same intervention. Recent reviews of hydrogen delivery strategies identify differences in stability, bioavailability, distribution and targeted delivery as some of the principal challenges in translating H₂ into clinical use.

Hydrogen water creates a brief oral exposure. With the TANVEA Hydrogen Water Bottle, the relevant questions therefore extend far beyond a maximum ppm value. Freshness, actual concentration at the moment of drinking, volume, technology and the entire exposure chain matter. The bottle is not “therapy in a bottle”. It is a practical technology that enables freshly prepared hydrogen-rich water to be consumed shortly after generation.

Hydrogen inhalation creates continuous pulmonary exposure during a dedicated period. With TANVEA Hydrogen Inhalers, the ml/min figure on the device is therefore not the only relevant parameter. Nominal generator output is not the same as the user’s actual inspired exposure, and safety cannot be reduced to the presence of one membrane or one technological label. Inhalation is a different exposure route, not “stronger hydrogen water”.

Hydrogen bathing creates another biological context: an aquatic environment, large-area contact between the skin and hydrogen-rich water, the physiology of immersion itself and the question of local and possible transdermal exposure. The new TANVEA Hydrogen Bath Generator provides a repeatable technological route for creating an H₂ environment in water, while Drink HRW RELIEF Hydrogen Bath Tablets offer a simple device-free alternative. In neither case does the word hydrogen alone tell us what biological dose has actually been created.

These routes therefore do not form a ladder of “weak – medium – strong therapy”. They form different exposure profiles. The best route is not currently a universal scientific category. We first need to know what type of exposure we want to create and why.

More H₂ on a display does not automatically mean more “therapy”

The word therapy can create a dangerous mental shortcut: if H₂ may have therapeutic potential, then more H₂ must mean a stronger therapeutic effect. Current science does not support such a simple linear relationship. With molecular hydrogen, actual exposure depends on the route of administration, concentration or inspired fraction, time, volume, losses, bioavailability and distribution. This is precisely why delivery remains one of the central questions in contemporary H₂ research.

A higher ppm value in water means more dissolved H₂ in the same volume under comparable conditions; it does not automatically mean a proportionally greater biological effect. A higher nominal inhaler flow means a greater generator output; it does not automatically mean the same proportional increase in the user’s FiH₂. More visible bubbling in a bath does not tell us how much dissolved H₂ remains in the water during the exposure itself.

TANVEA therefore does not want to sell “the biggest numbers”. We want people to understand the difference between a device parameter, real exposure and biological response.

Where marketing actually begins

Marketing does not begin simply when a brand talks about scientific research. It begins when important intermediate steps disappear. If a cellular mechanism is presented as a confirmed effect in humans, translation has been skipped. If one small RCT is presented as a universal benefit, replication and population have been skipped. If an inhalation study is used to sell a hydrogen water bottle, the exposure route has been skipped. If a technical ppm or ml/min figure is converted directly into a health promise, pharmacokinetics and biological response have been skipped.

This is where TANVEA wants to be different. Not by being sceptical of molecular hydrogen. On the contrary, current research is sufficiently interesting to deserve extremely serious attention. Trust, however, is not built by converting every new study into a sales sentence. It is built by understanding what a study showed, what it did not show and which product or situation its results can genuinely apply to.

Why TANVEA uses Hydrogen Systems™

This is why TANVEA did not build its architecture around the term Hydrogen Therapy. We use TANVEA Hydrogen Systems™ because the name describes reality more accurately. Molecular hydrogen is not one procedure. The outcome emerges from a system: the H₂ source, the way it is generated, the route of exposure, actual dose or inspired profile, duration, distribution, the person’s biological context and the subsequent response.

The term Systems also allows us to separate research into therapeutic applications of H₂ from what TANVEA offers within a wellness and recovery environment. We can discuss hydrogen medicine, RISP, mitochondrial quality control and clinical trials in depth without implying that a TANVEA hydrogen water bottle, inhaler or bath treats disease.

The distinction is fundamental. Hydrogen therapy is a research field. Hydrogen Systems™ are TANVEA’s framework for working responsibly with molecular hydrogen in a recovery environment.

How to read hydrogen-therapy claims without being a scientist

A person does not need a doctorate in redox biology to distinguish high-quality information from a marketing shortcut. A few logical questions are enough. What form of H₂ was used in the study? Which population was investigated? Were the experiments conducted in cells, animals or humans? Was the study controlled? How many participants were included? What was the exposure duration and actual dose? Was the outcome clinical, or was it only a biomarker? And does the product being sold even use the same route of exposure as the study being cited?

If marketing cannot answer these questions and instead relies primarily on words such as detox, anti-aging, recovery, strongest antioxidant or therapeutic concentration, an important part of the story is missing.

If, on the other hand, a technology can clearly explain what it creates, how it is measured, what the limitations of the evidence are and why that particular route makes sense, the person no longer needs grand promises. The decision can begin to rest on understanding.

Hydrogen therapy does not replace biological fundamentals

Even if future research confirms clear clinical relevance for molecular hydrogen in certain indications, one fundamental point does not change: H₂ is not a replacement for sleep, movement, nutrition, natural light rhythms, psychological recovery, functional circulation or medical care where it is needed.

Within TANVEA Biological Systems™, molecular hydrogen is therefore not another isolated “hack”. A separate Hydrogen Systems™ article explains its place as a protective and regulatory layer within the wider architecture of recovery. This article has a different purpose: to separate the scientific meaning of hydrogen therapy from the assumption that the existence of H₂ research turns every hydrogen product into a therapy.

This distinction allows TANVEA to support innovation without sacrificing scientific integrity.

Safety and non-medical framework

Hydrogen Systems™ at TANVEA belong within a wellness and recovery framework. They are not presented as diagnosis, treatment or a substitute for medical care. The fact that scientific publications use terms such as hydrogen therapy, therapeutic applications or hydrogen medicine describes the direction of biomedical research; it does not determine the clinical status of a particular consumer product. Contemporary reviews continue to highlight questions relating to bioavailability, stability, administration route, targeted distribution, safety and the need for further clinical research.

With inhalation, the physical properties of hydrogen and the safety architecture of the device must also be respected. With hydrogen water, technology quality, materials and preparation method matter. With bathing, the conditions of the bath itself, temperature, duration and the method of H₂ generation need to be considered; with tablet-based forms, the product composition matters as well. Anyone with health problems, a diagnosis, ongoing medication, recent surgery, an acute illness, pregnancy or another higher-risk condition should discuss the suitability of a specific recovery technology with a qualified healthcare professional.

The central idea

Hydrogen therapy is not an invented marketing term. It is a legitimate expression used in a growing area of biomedical research into molecular hydrogen H₂. Current literature includes human studies, clinical trials, mechanistic research and the development of entirely new delivery systems. At the same time, there is no single universal hydrogen therapy, no single dose and no single effect that can automatically be transferred across every form of H₂ use.

Research from 2025–2026 also suggests that the biological story of H₂ is probably substantially more complex than the original selective-antioxidant model. RISP and mitochondrial Complex III represent one important experimental line, oxidised Fe-porphyrins another, while broader reviews describe mitochondrial quality control, proteostasis and metabolic regulation as important research directions. The precise upstream mechanism remains unresolved.

This is exactly why TANVEA uses the name Hydrogen Systems™.

Not because we want to avoid the scientific term hydrogen therapy.

But because we want to interpret it more precisely.

Science may investigate H₂ as a therapeutic agent. TANVEA must simultaneously know exactly what can be claimed about a specific technology, a specific exposure and a specific biological context.

That is the difference between scientific interest and a therapeutic promise.

And trust is built precisely on that difference.

---

FAQ

Is hydrogen therapy a real scientific term?

Yes. The term molecular hydrogen therapy is used in scientific literature and in reviews of clinical studies. This does not mean, however, that one standardised therapy exists or that every consumer product containing or generating H₂ has a proven therapeutic effect.

Does the existence of clinical studies mean that hydrogen treats disease?

Not in such a general sense. Clinical data have to be interpreted according to the specific indication, population, route of exposure, dose, protocol and quality of the study. Research potential cannot automatically be converted into a universal therapeutic claim.

Is molecular hydrogen an antioxidant?

Historically, much of the field developed from the model of selective effects on highly reactive oxidative species. Current mechanistic understanding is broader and includes redox signaling, mitochondrial processes, proteostasis and metabolic regulation. The simple label “antioxidant” no longer captures the entire biological picture.

Is H₂ a stimulus?

It is not a performance stimulant in the conventional sense, and TANVEA does not position it as one. Experimental research does, however, suggest that H₂ can be biologically active and modulate mitochondrial regulatory responses, so it is not accurate to describe it as biologically inert.

Is hydrogen inhalation a “stronger therapy” than hydrogen water?

There is no scientifically established universal hierarchy of this kind. Inhalation and hydrogen-rich water create different exposure profiles, and they cannot be meaningfully compared using only one flow-rate or ppm number. Differences in delivery, bioavailability and distribution are among the key questions in current research.

Is a hydrogen bath hydrogen therapy?

In scientific or commercial language, hydrogen-rich bathing may be included within the broader field of H₂ applications. TANVEA describes it more precisely as one exposure route within Hydrogen Systems™, where the physiology of bathing needs to be distinguished from local H₂ contact and possible transdermal exposure.

Why does TANVEA use Hydrogen Systems™ rather than Hydrogen Therapy?

Because Hydrogen Systems™ more clearly separate TANVEA’s wellness and recovery framework from the medical implications of the word therapy. The term also allows the entire system to be evaluated from H₂ source and exposure through distribution to biological response and quality of evidence.

---

SCIENTIFIC FOUNDATION

This article is informational, educational and non-medical in nature. The term hydrogen therapy is used here in accordance with scientific literature as the name of a molecular-hydrogen research field, not as a universal therapeutic promise.

The updated scientific framework retains the historical work of Ohsawa and colleagues, modern redox biology and the 2023 clinical review, while adding major evidence from 2025–2026. Negishi et al. introduced the experimental RISP–Complex III–LONP1–UPRmt line; subsequent scientific discussion cautioned that RISP may not represent the sole primary entry point of H₂ signaling. Reviews of mitochondrial quality control have broadened the framework toward proteostasis and metabolic regulation, while Sano et al. developed the oxidised Fe-porphyrin and hematin mechanism in 2026. At the same time, the Advanced Drug Delivery Reviews analysis emphasises that clinical translation of H₂ cannot be separated from issues of stability, bioavailability, timing and delivery.

The 2026 human RCT is included as an example of current clinical research, not as proof of a universal performance or recovery effect. It involved only 13 male university athletes and one specific repeated-sprint protocol.

SELECTED SCIENTIFIC SOURCES

Ohsawa I., Ishikawa M., Takahashi K. et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine. 2007;13:688–694. DOI: 10.1038/nm1577.

Ohta S. Molecular hydrogen as a novel antioxidant: overview of the advantages of hydrogen for medical applications. Methods in Enzymology. 2015;555:289–317.

Schieber M., Chandel N.S. ROS Function in Redox Signaling and Oxidative Stress. Current Biology. 2014.

Johnsen H.M., Hiorth M., Klaveness J. Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. Molecules. 2023;28(23):7785. DOI: 10.3390/molecules28237785.

Negishi S. et al. The Rieske iron-sulfur protein is a primary target of molecular hydrogen. Redox Biology. 2025;88:103952. DOI: 10.1016/j.redox.2025.103952.

Ostojic S.M. Revisiting molecular hydrogen signaling in mitochondria: Is the Rieske protein the entry point or a downstream sentinel? Redox Biology. 2026;89:104003. DOI: 10.1016/j.redox.2026.104003.

Nguyen L.-D.-H. et al. Advances in hydrogen delivery strategies for therapeutic applications. Advanced Drug Delivery Reviews. 2026;228:115734. DOI: 10.1016/j.addr.2025.115734.

Li F., Jing Y. et al. Molecular Hydrogen as a Regulator of Mitochondrial Quality Control and Metabolic Reprogramming. International Journal of Molecular Sciences. 2026;27(11):4948. DOI: 10.3390/ijms27114948.

Sano M., Shibuya M., Uchinoumi H. et al. Paradigm shift in hydrogen medicine: Target molecules and catalytic mechanisms elucidated at the atomic level. Journal of Cardiology. Published online 29 August 2026. DOI: 10.1016/j.jjcc.2026.08.007.

Chen Z., Chi M., Liu R., Ma L., Shen Y. Effects of Hydrogen-Rich Water Supplementation on Exercise Performance, Autonomic Nervous System Recovery, and Blood Lactate Concentration During Repeated Sprint Exercise in Male University Athletes. Journal of Sports Science and Medicine. 2026;25(3):744–752. DOI: 10.52082/jssm.2026.744.